275 related articles for article (PubMed ID: 12544410)
1. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial.
Gibb DM; Goodall RL; Giacomet V; McGee L; Compagnucci A; Lyall H;
Pediatr Infect Dis J; 2003 Jan; 22(1):56-62. PubMed ID: 12544410
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children.
van Rossum AM; Bergshoeff AS; Fraaij PL; Hugen PW; Hartwig NG; Geelen SP; Wolfs TF; Weemaes CM; De Groot R; Burger DM
Pediatr Infect Dis J; 2002 Aug; 21(8):743-7. PubMed ID: 12192162
[TBL] [Abstract][Full Text] [Related]
3. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
Hoffmann F; Funk M; Linde R; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH; Wintergerst U
Eur J Med Res; 2002 Jul; 7(7):330-4. PubMed ID: 12176683
[TBL] [Abstract][Full Text] [Related]
4. Adherence to medication regimens among children with human immunodeficiency virus infection.
Reddington C; Cohen J; Baldillo A; Toye M; Smith D; Kneut C; Demaria A; Bertolli J; Hsu HW
Pediatr Infect Dis J; 2000 Dec; 19(12):1148-53. PubMed ID: 11144374
[TBL] [Abstract][Full Text] [Related]
5. Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children.
Spector SA; Hsia K; Yong FH; Cabral S; Fenton T; Fletcher CV; McNamara J; Mofenson LM; Starr SE
J Infect Dis; 2000 Dec; 182(6):1769-73. PubMed ID: 11069252
[TBL] [Abstract][Full Text] [Related]
6. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection.
Van Dyke RB; Lee S; Johnson GM; Wiznia A; Mohan K; Stanley K; Morse EV; Krogstad PA; Nachman S;
Pediatrics; 2002 Apr; 109(4):e61. PubMed ID: 11927734
[TBL] [Abstract][Full Text] [Related]
7. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
[TBL] [Abstract][Full Text] [Related]
8. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.
Starr SE; Fletcher CV; Spector SA; Yong FH; Fenton T; Brundage RC; Manion D; Ruiz N; Gersten M; Becker M; McNamara J; Mofenson LM; Purdue L; Siminski S; Graham B; Kornhauser DM; Fiske W; Vincent C; Lischner HW; Dankner WM; Flynn PM
N Engl J Med; 1999 Dec; 341(25):1874-81. PubMed ID: 10601506
[TBL] [Abstract][Full Text] [Related]
10. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.
Nieuwkerk PT; Sprangers MA; Burger DM; Hoetelmans RM; Hugen PW; Danner SA; van Der Ende ME; Schneider MM; Schrey G; Meenhorst PL; Sprenger HG; Kauffmann RH; Jambroes M; Chesney MA; de Wolf F; Lange JM;
Arch Intern Med; 2001 Sep; 161(16):1962-8. PubMed ID: 11525698
[TBL] [Abstract][Full Text] [Related]
11. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.
Nachman SA; Stanley K; Yogev R; Pelton S; Wiznia A; Lee S; Mofenson L; Fiscus S; Rathore M; Jimenez E; Borkowsky W; Pitt J; Smith ME; Wells B; McIntosh K
JAMA; 2000 Jan; 283(4):492-8. PubMed ID: 10659875
[TBL] [Abstract][Full Text] [Related]
12. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).
Pellegrin I; Breilh D; Montestruc F; Caumont A; Garrigue I; Morlat P; Le Camus C; Saux MC; Fleury HJ; Pellegrin JL
AIDS; 2002 Jul; 16(10):1331-40. PubMed ID: 12131209
[TBL] [Abstract][Full Text] [Related]
13. Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children.
Saitoh A; Hsia K; Fenton T; Powell CA; Christopherson C; Fletcher CV; Starr SE; Spector SA
J Infect Dis; 2002 May; 185(10):1409-16. PubMed ID: 11992275
[TBL] [Abstract][Full Text] [Related]
14. Differences in durability of treatment with initial PI-based regimens.
Pérez-Elías MJ; Moreno A; Moreno S; Antela A; Dronda F; Muñoz V; Casado JL; Quereda C; Lopez D; Navas E
HIV Clin Trials; 2003; 4(6):391-9. PubMed ID: 14628282
[TBL] [Abstract][Full Text] [Related]
15. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate.
Krogstad P; Wiznia A; Luzuriaga K; Dankner W; Nielsen K; Gersten M; Kerr B; Hendricks A; Boczany B; Rosenberg M; Jung D; Spector SA; Bryson Y
Clin Infect Dis; 1999 May; 28(5):1109-18. PubMed ID: 10452644
[TBL] [Abstract][Full Text] [Related]
16. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team.
Wiznia A; Stanley K; Krogstad P; Johnson G; Lee S; McNamara J; Moye J; Jackson JB; Mendez H; Aguayo R; Dieudonne A; Kovacs A; Bamji M; Abrams E; Rana S; Sever J; Nachman S
AIDS Res Hum Retroviruses; 2000 Aug; 16(12):1113-21. PubMed ID: 10954886
[TBL] [Abstract][Full Text] [Related]
17. Virologic response of nine therapy-experienced children receiving 64 weeks of nelfinavir salvage therapy.
Vavro CL; Zimmermann AM; McClernon DR; Kehne SL; Martel LA; Valentine ME; McKinney RE
Ann N Y Acad Sci; 2000 Nov; 918():381-5. PubMed ID: 11131731
[No Abstract] [Full Text] [Related]
18. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of nelfinavir in patients switched from ritonavir/saquinavir combination antiretroviral therapy.
Hellinger JA; Cohen CJ; Stein AJ; Gallant JE; Gathe J; Keiser P
HIV Clin Trials; 2000; 1(2):25-8. PubMed ID: 11590495
[TBL] [Abstract][Full Text] [Related]
20. Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors.
Yin DE; Ludema C; Cole SR; Golin CE; Miller WC; Warshaw MG; McKinney RE;
PLoS One; 2020; 15(11):e0242405. PubMed ID: 33226999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
